Select Page

MEDICINES

 

NEW GAME, NEW RULES

 

Pathways to better and affordable medicines.

                   At the European Health Forum,Gastein

Organised by Open Society Foundations (OSF) in cooperation with European Public Health Alliance (EPHA) and European Public Health Association (EUPHA)

 

2016 was a year of political recognition that imbalances exist in the pharmaceutical system along with widespread concerns about the sustainability of healthcare systems in Europe. The price of both old and new medicines has been rising dramatically, leading to rationing of medicines for patients and other access to treatment challenges. These problems are the result of a dysfunctional R&D system that  prioritises profits over public health imperatives and individual patients’ needs.

This session will respond to the calls by EU and national policy-makers for actionable policy recommendations. It will articulate a set of short, mid and long-term policy proposals in the area of incentives for drug development and the need for public health needs-driven regulatory reform in Europe, to guarantee genuine therapeutic advance for the benefit of all patients.

Programme

 

Welcome & introductory remarks

KITI KAJANA PHILLIPS, Program Officer, Access to Medicines & Innovation, Public Health Program, Open Society Foundations (OSF)

Panel I - The access to medicines problems in Europe: What can governments do?

Interventions from

MARCEL VAN RAAIJ, PhD, Director Medicines & Medical Technology, Ministry of Health, Welfare and Sport, The Netherlands

CLEMENS MARTIN AUER, PhD, Director General, Federal Ministry of Health & Women’s Affairs, Austria and President, European Health Forum Gastein

MELANIE KENNEDY, Patient Advocate, Just Treatment, UK

MARTIN MUNTE, President, Pharmig – Association of the Austrian Pharmaceutical Industry; and Chief Executive Officer, Amgen

YANNIS NATSIS, Policy Manager, Universal Access & Affordable Medicines, European Public Health Alliance (EPHA)

Moderation

MARTIN MCKEE, Professor, London School of Hygiene and Tropical Medicine

Panel II – Do we get the medicines we need and can afford?

Interventions from:

SUERIE MOON PhD, Director of Research at the Global Health Centre, Graduate Institute of International and Development Studies, Geneva and Adjunct Lecturer on Global Health at the Harvard T.H. Chan School of Public Health

COURTNEY DAVIS, PhD, Director of the Masters in Medicine, Health and Public Policy, Department of Global Health and Social Medicine, Kings College, London

AJAY AGGARWAL, MD, Consultant Clinical Oncologist, Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine

LIVIO GARATTINI, PhD, Director, Angelo & Angela Valenti – Centre of Health Economics (CESAV), Mario Negri Institute

Moderation

DEBORAH COHEN, Investigations Editor, British Medical Journal (BMJ)

Concluding remarks

YANNIS NATSIS, Policy Manager, Universal Access & Affordable Medicines, European Public Health Alliance (EPHA)

MEDICINES: NEW GAMES, NEW RULES

Social Media

Made with love by COCREATE

SUBSCRIBE TO OUR MAILING LIST

We publish our newsletter ten times a year to keep you informed about the latest news on public health in Europe. You can receive it directly in your mailbox.
First Name
Last Name
Email address
Secure and Spam free...